Advanced diagnostic and prognostic solutions for urological cancer care 

No matter which test(s) you receive from our growing portfolio of traditional and breakthrough products and services, rest assured they are backed by our superior clinical expertise and the
highest level of customer support.

Press Release

Study Demonstrates Cost-effectiveness of New Assay to Inform Treatment Decisions Compared to Guidelines-based Care

Data published in The Oncologist support use of ProMark® as a likely cost-effective addition to current guidelines for management of Gleason 3+3 and 3+4 early-stage prostate cancer.

read article
Press Release

Metamark Announces Publication of Clinical Validation Study for the ProMark™ Prostate Cancer Prognostic Test

Metamark announced today that results of its clinical validation study for the ProMark™ prostate cancer test were published online in Clinical Cancer Research.

read article
Displaying results 5-6 (of 13)
 |<  <  1 - 2 - 3 - 4 - 5 - 6 - 7  >  >|